ArticleJournal of cardiothoracic surgery2025
Comparison of segmentectomy and lobectomy for non-small cell lung cancer with visceral pleural invasion.
Article in Journal of cardiothoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVisceral pleural invasion (VPI) is known to have a significant impact on staging and prognosis in NSCLC and is an important factor in determining surgical strategy. The aim of this study was to compare the outcomes of surgical procedure (segmentectomy vs. lobectomy) with VPI positive patients.
methodsA retrospective study was conducted on 218 VPI positive NSCLC patients were studied, with the segmentetomy group (n = 42) designated as cohort.1, cases with tumor diameter less than 2 cm (n = 22) designated as cohort.2, and cases with greater than 2 cm (n = 20) designated as cohort.3. Each group and 150 cases of lung lobectomy were analyzed. Cause of death and recurrence mode were investigated.
resultsThere was no difference in OS, DSS and RFS between segmentectomy and lobectomy after propensity matched analysis. There was no difference in OS and RFS in the group of cases < 2 cm. In patients with tumors > 2 cm, recurrence-free survival was numerically higher in the lobectomy group than in the segmentectomy group, although this difference was not statistically significant (p = 0.08). There was no difference in lung cancer deaths, but there was a trend toward more deaths from multiple disease in the lobectomy group (p = 0.07), and pleural dissemination recurrence was significantly more common in the segmentectomy group than in the lobectomy group in the > 2 cm group (p = 0.03).
conclusionIn patients with VPI-positive lung cancer, segmentectomy may offer a better prognosis for those with tumors measuring < 2 cm. Nevertheless, lobectomy should be considered first for patients with tumors measuring > 2 cm. Our study provides novel insights by stratifying outcomes based on tumor size, highlighting pleural dissemination risk and death causes, which may support individualized surgical decision-making. Although no statistically significant difference was found, lobectomy may be more appropriate for patients with tumors > 2 cm based on the observed recurrence patterns and potential for better local control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.